Ekram Ismail Fagiree

Dr. Ekram Ismail Fagiree


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
NANahlah Makki Almansour
Nahlah Makki Almansour
Khaled S. AllemailemKhaled S. Allemailem
Khaled S. Allemailem
AAAbeer Abas Abd El Aty
Abeer Abas Abd El Aty
Ekram Ismail FagireeEkram Ismail Fagiree
Ekram Ismail Fagiree
Mahmoud A. A. IbrahimMahmoud A. A. Ibrahim
Mahmoud A. A. Ibrahim
The Bcl-2 protein has a vital function in controlling the programmed cell doom of mitochondria. If programmed cell death signals are obstructed, an imbalance between cell survival and death will occur, which is a significant reason for cancer. Therefore, the Bcl-2 protein was identified as a possible therapeutic target for carcinoma treatment. Herein, the Natural Products Atlas (NPAtlas) compounds were virtually screened, seeking potent inhibitors towards the Bcl-2 protein. The performance of AutoDock Vina software to predict the docking score and pose of the investigated compounds was first validated according to the available experimental data. Based on the validated AutoDock Vina parameters, the NPAtlas database was filtered against the Bcl-2 protein. The natural compounds with docking scores less than that of the venetoclax (calc. −10.6 kcal/mol) were submitted to MD simulations, followed by MM-GBSA binding energy calculations. According to MM-GBSA//200 ns MD simulations, saquayamycin F (NPA002200) demonstrated promising binding affinity with a ΔGbinding value of −53.9 kcal/mol towards the Bcl-2 protein when compared to venetoclax (ΔGbinding = −50.6 kcal/mol). The energetical and structural analyses showed a great constancy of the saquayamycin F inside the Bcl-2 protein active site. Moreover, the ADMET and drug-likeness features of the saquayamycin F were anticipated, indicating its good oral bioavailability. According to in silico computations, saquayamycin F is proposed to be used as a therapeutic agent against the wild-type Bcl-2 protein and warrants further experimental assays.

14 July 2026
Verified
Book Chapter
Open access
PDF file
Ekram Ismail FagireeEkram Ismail Fagiree
Ekram Ismail Fagiree
Vitamins are essential micronutrients that exert critical regulatory effects on both innate and adaptive immune responses. Beyond their classical metabolic functions, vitamins participate in immune cell differentiation, cytokine signaling, oxidative stress control, and inflammatory modulation through interconnected molecular pathways. This chapter critically reviews the immunomodulatory roles of vitamins A, D, E, B-complex, and C, emphasizing their molecular mechanisms, clinical implications, and therapeutic relevance in inflammatory and immune-mediated disorders. Evidence from experimental, clinical, and epidemiological studies demonstrates that vitamin deficiencies impair epithelial barrier integrity, dysregulate cytokine production, weaken antioxidant defense systems, and alter immune-cell signaling pathways, including NF-κB, MAPK, and JAK-STAT. In contrast, adequate vitamin status contributes to immune homeostasis, enhanced host defense, and regulation of chronic inflammatory responses. The chapter also integrates the overlapping pathways shared among vitamins, including antioxidant protection, epigenetic regulation, cytokine modulation, and immune-cell signaling, highlighting their coordinated rather than isolated actions. Although vitamin supplementation has shown promising therapeutic potential, clinical outcomes remain inconsistent because of differences in dosage, baseline nutritional status, disease characteristics, and study design. Further research is needed to clarify optimal supplementation strategies, long-term safety, and synergistic interactions among vitamins. A better understanding of these integrated mechanisms may contribute to the development of precision nutrition approaches and personalized therapeutic strategies for the prevention and management of immune-mediated and inflammatory diseases.

3 March 2022
Verified
Book Chapter
Closed access
Ekram Ismail FagireeEkram Ismail Fagiree
Ekram Ismail Fagiree
MSMohammed Bahaa Eldeen Ahmed Saad
Mohammed Bahaa Eldeen Ahmed Saad
AEAisha Abass Elsadig
Aisha Abass Elsadig
In the present research, hydatid cysts were extracted from camel livers and lungs and protoscoleces were separated aseptically at the Tambool slaughter house. Thirty 6-week-old Swiss mice (25-30 gramme body weight males) were divided into two groups of six each: a prophylactic group was given 150 ml/kg albendazole and mebendazole was given directly after injection with 2000 protoscoleces intraperitoneally for ten days. Albendazole and Mebendazole are most frequently prescribed for treatment of intestinal nematode infections. The treated group received a dose of 300 mL/kg of albendazole and mebendazole every 4 days, separated by 2 days, for 24 days, and after 6 months of protoscoleces inoculation, the two groups, along with the control group, were sacrificed and necropsied. The findings revealed a significant difference in the development of hydatid cysts. Inside the mice, a small number of cysts were observed in the groups treated with albendazole and mebendazole compared to the control group; however, albendazole was more efficacious than mebendazole, with albendazole reaching 97 percent efficiency and mebendazole reaching nearly 50 percent efficiency. This suggests that albendazole may be the drug of choice for the treatment of hydatid cysts.